title: Impact of presentation of research results on likelihood of prescribing medications to patients with left ventricular dysfunction.
abstract: This study was conducted to evaluate willingness to prescribe medication based on identical data presented in different outcome terms to health professionals of varied discipline, geographic location, and level of training. Cross-sectional survey using a self-administered questionnaire was performed in 400 health professionals (physicians, pharmacists, physicians-in-training, and pharmacy students) in the United States and Europe. Data reflecting a clinical trial were presented in 6 outcome terms: 3 terms describing identical mortality (relative risk reduction, absolute risk reduction, and number of patients needed to be treated to prevent 1 death); and 3 distractors (increased life expectancy, decreased hospitalization rate, and decreased cost). Willingness to prescribe and rank order of medication preference assuming willingness to prescribe were measured. The results of the study showed that willingness to prescribe and first choice preference were significantly greater when study results were presented as relative risk reduction than when identical mortality data were presented as absolute risk reduction or number of patients needed to be treated to avoid 1 death (p <0.001). Increase in life expectancy was the most influential distractor. In conclusion, this study, performed in the era of "evidence-based medicine," demonstrates that the method of reporting research trial results has significant influence on health professionals' willingness to prescribe. The high numerical value of relative risk reduction and the concrete and tangible quality of increased life expectancy exert greater influence on health professionals than other standard outcome terms.
authors.affiliation: Center for Disease Management and Clinical Outcomes, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick 08903-0019, USA.
authors.forename: C R
authors.initials: CR
authors.lastname: Lacy
authors.forename: J A
authors.initials: JA
authors.lastname: Barone
authors.forename: D C
authors.initials: DC
authors.lastname: Suh
authors.forename: P L
authors.initials: PL
authors.lastname: Malini
authors.forename: M
authors.initials: M
authors.lastname: Bueno
authors.forename: D M
authors.initials: DM
authors.lastname: Moylan
authors.forename: J B
authors.initials: JB
authors.lastname: Kostis
mesh_terms: D002317:Cardiovascular Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003430:Cross-Sectional Studies; D011307:Drug Prescriptions; D004363:Drug Utilization; D005060:Europe; D019317:Evidence-Based Medicine; D006801:Humans; D010818:Practice Patterns, Physicians'; D011795:Surveys and Questionnaires; D014481:United States; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy*
chemical_list: D002317:Cardiovascular Agents